Seagen (SGEN) – Major News
-
Seagen (SGEN) Misses Q3 EPS by 33c
-
Seagen (SGEN) Misses Q2 EPS by 33c
-
Seagen (SGEN) Misses Q1 EPS by 10c
-
Pfizer (PFE) Acquires Seagen (SGEN) for $43B or $229/sh
-
Pfizer (PFE) is in early talks to acquire Seagen (SGEN) - WSJ
-
Seagen (SGEN) Tops Q4 EPS, Revenue
-
Seagen (SGEN) Misses Q3 EPS by 8c
-
Seagen (SGEN) Tops Q2 EPS by 38c, Sales Beat; Raises Outlook
-
Merck (MRK) in advanced talks to acquire Seagen (SGEN) for more than $200 per share - WSJ
-
Merck (MRK), Seagen (SGEN) Takeover Talks Heat Up - WSJ
-
Merck (MRK) Eyes Purchase of Seagen (SGEN) - WSJ
-
Seagen (SGEN) Tops Q1 EPS by 26c, Offers Guidance
-
Seagen (SGEN) Misses Q4 EPS by 13c
-
Seagen (SGEN) Misses Q3 EPS by $1.04
-
Seagen (SGEN) Tops Q2 EPS by 13c
-
Seagen (SGEN) Misses Q1 EPS by 6c, Revenues Miss
-
Seagen (SGEN) Tops Q4 EPS by 3c
-
Seagen (SGEN) Tops Q3 EPS by $3.00, Revenues Beat
-
Seattle Genetics (SGEN) Tops Q2 EPS by 51c, Revenues Beat; Offers FY20 Revenue Guidance
-
Seattle Genetics (SGEN) Misses Q1 EPS by 19c, Revenues Miss; Maintains FY20 Sales Outlook
-
Seattle Genetics (SGEN) Tops Q4 EPS by 59c, Revenues Beat; Offers FY20 Sales Outlook Below Consensus
-
Seattle Genetics (SGEN) Misses Q3 EPS by 19c, Revenues Beat; Raises FY19 Revenue Outlook
-
Seattle Genetics (SGEN) Misses Q2 EPS by 11c, Revenues Beat; Offers FY19 Revenue Guidance
-
Seattle Genetics (SGEN) Tops Q1 EPS by 21c, Revenues Beat; Offers FY19 Revenue Mid-Point Below Consensus
-
Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
-
Seattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook
-
Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
-
Seattle Genetics (SGEN) Reports Q1 Loss of $0.73
-
Seattle Genetics (SGEN) Tops Q4 EPS by 2c, Beats on Revenues
-
Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
-
Seattle Genetics (SGEN) Tops Q2 EPS by 3c
-
Seattle Genetics (SGEN) Reports In-Line Q1 EPS
-
Seattle Genetics (SGEN) Misses Q4 EPS by 5c
-
Seattle Genetics (SGEN) FDA Places Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine
-
Seattle Genetics (SGEN) Tops Q3 EPS by 6c
-
Seattle Genetics (SGEN) Tops Q2 EPS by 9c
-
Seattle Genetics (SGEN) Misses Q1 EPS by 6c
-
Seattle Genetics (SGEN) Tops Q4 EPS by 2c
-
Seattle Genetics (SGEN) Misses Q3 EPS by 1c
-
Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
-
Seattle Genetics (SGEN) Tops Q4 EPS by 3c
-
Seattle Genetics (SGEN) Tops Q3 EPS by 11c
-
Seattle Genetics Inc. (SGEN) Tops Q2 EPS by 9c
-
Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 8c
-
Seattle Genetics Inc. (SGEN) Tops Q4 EPS by 11c
-
Seattle Genetics Inc. (SGEN) Reports Q3 Loss of $0.19/sh
-
Seattle Genetics Inc. (SGEN) Post Much Smaller Q2 Loss
-
Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 6c
-
Seattle Genetics (SGEN) in Focus After Tops Q4 EPS by 2c, Provides Outlook
-
Seattle Genetics Inc. (SGEN) Tops Q3 EPS by 3c
Back to SGEN Stock Lookup